Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Trames Bio, Inc. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners, meaning that each active matter is being handled by a separate official. The portfolio is localized within 1 distinct art unit, which indicates that the technical subject matter of these biotechnology applications is being reviewed within the same specialized group at the patent office. This concentration in a single art unit can help in maintaining a consistent technical narrative across the pending cases.
The busiest examiner for the portfolio is RIGA, MICHAEL ANGELO, who is responsible for 1 pending office action. With a total of 2 pending office actions, the workload is split between the two examiners. Practitioners should be prepared to address the specific requirements of the Biotechnology & Pharmaceuticals area while managing the distinct examination styles of the two officials. The presence of a single art unit suggests that the overarching technical standards will be consistent, even if the individual examiners provide different types of feedback on the pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RIGA, MICHAEL ANGELO | 1 | 57.1% | +61.2% |
| DEBERRY, REGINA M | 1 | 50.1% | +30.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18729329 | EXPRESSION CASSETTES FOR TREATING EPILEPSY AND NEUROPATHIC PAIN | RIGA, MICHAEL ANGELO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18022358 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | DEBERRY, REGINA M | 4d overdue |
| 18729329 | EXPRESSION CASSETTES FOR TREATING EPILEPSY AND NEUROPATHIC PAIN | RIGA, MICHAEL ANGELO | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18729329 | EXPRESSION CASSETTES FOR TREATING EPILEPSY AND NEUROPATHIC PAIN | RIGA, MICHAEL ANGELO | — | §102§103§112Other | Non-Final OA | — | Pending | Jul 16, 2024 |
| 18022358 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | DEBERRY, REGINA M | 1647 | DP | Final Rejection | 4d overdue | Pending | Feb 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial